Clopidogrel/Acetylsalicylic acid Teva

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
28-04-2017
Produktens egenskaper Produktens egenskaper (SPC)
28-04-2017

Aktiva substanser:

clopidogrel, Acetylsalicylic acid

Tillgänglig från:

Teva Pharma B.V.

ATC-kod:

B01AC30

INN (International namn):

clopidogrel, acetylsalicylic acid

Terapeutisk grupp:

combinations

Terapiområde:

Acute Coronary Syndrome; Myocardial Infarction

Terapeutiska indikationer:

Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed‑dose combination medicinal product for continuation of therapy in:Non‑ST segment elevation acute coronary syndrome (unstable angina or non‑Q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

Produktsammanfattning:

Revision: 1

Bemyndigande status:

Withdrawn

Tillstånd datum:

2014-09-01

Bipacksedel

                                59
B. PACKAGE LEAFLET
Medicinal product no longer authorised
60
PACKAGE LEAFLET: INFORMATION FOR THE USER
CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA 75 MG/75 MG FILM-COATED TABLETS
clopidogrel/acetylsalicylic acid
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4. .
WHAT IS IN THIS LEAFLET
1.
What Clopidogrel/Acetylsalicylic acid Teva is and what it is used for
2.
What you need to know before you take Clopidogrel/Acetylsalicylic acid
Teva
3.
How to take Clopidogrel/Acetylsalicylic acid Teva
4.
Possible side effects
5.
How to store Clopidogrel/Acetylsalicylic acid Teva
6.
Contents of the pack and other information
1.
WHAT CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA IS AND WHAT IT IS USED FOR
Clopidogrel/Acetylsalicylic acid Teva contains clopidogrel and
acetylsalicylic acid (ASA) and belongs
to a group of medicines called antiplatelet medicinal products.
Platelets are very small structures in the
blood which clump together during blood clotting. By preventing this
clumping in some types of blood
vessels (called arteries), antiplatelet medicinal products reduce the
chances of blood clots forming (a
process called atherothrombosis).
Clopidogrel/Acetylsalicylic acid Teva is taken by adults to prevent
blood clots forming in hardened
arteries which can lead to atherothrombotic events (such as stroke,
heart attack, or death).
You have been prescribed Clopidogrel/Acetylsalicylic acid Teva in
place of the two separate
medicines, clopidogrel and ASA, to help prevent blood clots because
you have experienced a severe
type of chest pain known as ‘unst
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 75 mg of
acetylsalicylic acid (ASA).
Excipient with known effect:
Each film-coated tablet contains 102.6 mg of lactose (as lactose
monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Yellow, film-coated capsule shaped tablets. The tablets have a length
of 14.0 mm and a width of
6.8 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention
of atherothrombotic events in
adult patients already taking both clopidogrel and acetylsalicylic
acid (ASA).
Clopidogrel/Acetylsalicylic acid Teva is a fixed-dose combination
medicinal product for continuation
of therapy in:

Non-ST segment elevation acute coronary syndrome (unstable angina or
non-Q-wave
myocardial infarction) including patients undergoing a stent placement
following percutaneous
coronary intervention

ST segment elevation acute myocardial infarction in medically treated
patients eligible for
thrombolytic therapy
For further information please refer to section 5.1.
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology

Adults and elderly population
Clopidogrel/Acetylsalicylic acid Teva should be given as a single
daily 75 mg/75 mg dose.
Clopidogrel/Acetylsalicylic acid Teva is used following initiation of
therapy with clopidogrel and
ASA given separately.
-
_In patients with non-ST segment elevation acute coronary syndrome_
(unstable angina or
non-Q-wave myocardial infarction): The optimal duration of treatment
has not been formally
established. Clinical trial data support use up to 12 months, and the
maximum benefit was seen
at 3 months (see section 5.1). If the use of the combination of
clopidogrel/acetylsalic
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 28-04-2017
Produktens egenskaper Produktens egenskaper bulgariska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 28-04-2017
Bipacksedel Bipacksedel spanska 28-04-2017
Produktens egenskaper Produktens egenskaper spanska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 28-04-2017
Bipacksedel Bipacksedel tjeckiska 28-04-2017
Produktens egenskaper Produktens egenskaper tjeckiska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 28-04-2017
Bipacksedel Bipacksedel danska 28-04-2017
Produktens egenskaper Produktens egenskaper danska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 28-04-2017
Bipacksedel Bipacksedel tyska 28-04-2017
Produktens egenskaper Produktens egenskaper tyska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 28-04-2017
Bipacksedel Bipacksedel estniska 28-04-2017
Produktens egenskaper Produktens egenskaper estniska 28-04-2017
Bipacksedel Bipacksedel grekiska 28-04-2017
Produktens egenskaper Produktens egenskaper grekiska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 28-04-2017
Bipacksedel Bipacksedel franska 28-04-2017
Produktens egenskaper Produktens egenskaper franska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 28-04-2017
Bipacksedel Bipacksedel italienska 28-04-2017
Produktens egenskaper Produktens egenskaper italienska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 28-04-2017
Bipacksedel Bipacksedel lettiska 28-04-2017
Produktens egenskaper Produktens egenskaper lettiska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 28-04-2017
Bipacksedel Bipacksedel litauiska 28-04-2017
Produktens egenskaper Produktens egenskaper litauiska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 28-04-2017
Bipacksedel Bipacksedel ungerska 28-04-2017
Produktens egenskaper Produktens egenskaper ungerska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 28-04-2017
Bipacksedel Bipacksedel maltesiska 28-04-2017
Produktens egenskaper Produktens egenskaper maltesiska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 28-04-2017
Bipacksedel Bipacksedel nederländska 28-04-2017
Produktens egenskaper Produktens egenskaper nederländska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 28-04-2017
Bipacksedel Bipacksedel polska 28-04-2017
Produktens egenskaper Produktens egenskaper polska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 28-04-2017
Bipacksedel Bipacksedel portugisiska 28-04-2017
Produktens egenskaper Produktens egenskaper portugisiska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 28-04-2017
Bipacksedel Bipacksedel rumänska 28-04-2017
Produktens egenskaper Produktens egenskaper rumänska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 28-04-2017
Bipacksedel Bipacksedel slovakiska 28-04-2017
Produktens egenskaper Produktens egenskaper slovakiska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 28-04-2017
Bipacksedel Bipacksedel slovenska 28-04-2017
Produktens egenskaper Produktens egenskaper slovenska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 28-04-2017
Bipacksedel Bipacksedel finska 28-04-2017
Produktens egenskaper Produktens egenskaper finska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 28-04-2017
Bipacksedel Bipacksedel svenska 28-04-2017
Produktens egenskaper Produktens egenskaper svenska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 28-04-2017
Bipacksedel Bipacksedel norska 28-04-2017
Produktens egenskaper Produktens egenskaper norska 28-04-2017
Bipacksedel Bipacksedel isländska 28-04-2017
Produktens egenskaper Produktens egenskaper isländska 28-04-2017
Bipacksedel Bipacksedel kroatiska 28-04-2017
Produktens egenskaper Produktens egenskaper kroatiska 28-04-2017
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 28-04-2017

Sök varningar relaterade till denna produkt